Related Experiment Videos
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
J L C M Dorne1, K Walton, W Slob
1Clinical Pharmacology Group, University of Southampton, Biomedical Sciences Building, Bassett Crescent East, Southampton SO16 7PX, UK.
Summary
Human variability in CYP2D6 enzyme activity leads to significant differences in drug exposure. Understanding these variations is crucial for accurate risk assessment and determining appropriate uncertainty factors for drug safety.
Area of Science:
- Pharmacology
- Drug Metabolism and Pharmacokinetics
- Biotechnology
Background:
- Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme responsible for metabolizing a significant number of drugs.
- Interindividual variability in CYP2D6 activity can lead to substantial differences in drug exposure and response.
- Accurate quantification of this variability is essential for robust risk assessment and establishing appropriate safety factors.
Purpose of the Study:
- To quantify human variability in the pharmacokinetics of CYP2D6 substrates.
- To analyze the impact of different CYP2D6 metabolizer phenotypes (extensive, intermediate, poor) on drug exposure.
- To evaluate the adequacy of current uncertainty factors for risk assessment across various subpopulations.
Main Methods:
- Analysis of published pharmacokinetic data from healthy adults, categorized by CYP2D6 metabolizer status.
- Inclusion of studies with oral and intravenous dosing, examining parameters related to chronic and acute drug exposure.
- Subgroup analyses considering age, ethnicity, and disease state.
Main Results:
- High interindividual variability in oral drug exposure was observed in non-phenotyped individuals and extensive metabolizers (EMs).
- Intermediate (SEMs) and poor metabolizers (PMs) exhibited significantly increased oral drug exposure compared to EMs.
- Existing uncertainty factors, such as the default of 3.16, are insufficient to cover the kinetic variability in most subpopulations, particularly PMs and children.
Conclusions:
- The extent of CYP2D6 involvement in drug metabolism is critical for estimating CYP2D6-related uncertainty factors.
- Default uncertainty factors are inadequate for many populations, necessitating individualized or population-specific factors.
- This study highlights the need for refined risk assessment strategies considering CYP2D6 genetic polymorphism and its impact on drug safety.